Cited 0 times in
PS2-3 Neoadjuvant pembrolizumab/placebo + chemo, followed by adjuvant pembrolizumab/placebo in early TNBC: Asian subgroup
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.